Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alzheimer’s Disease – Special Topics – Special Topics: Physician Awareness, Perceptions, and Use of Leqembi (US)

Login to access report north_east
Contact sales account_box

Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS covering the drug in line with its label and broadening reimbursement of PET scans used to establish diagnoses and determine treatment eligibility, Leqembi is poised to capitalize on the unfulfilled potential for an AD DMT. However, logistic hurdles on the path to diagnosis and treatment initiation must be overcome to unlock the full potential of a DMT in the AD market. This survey-based report assesses awareness, perceptions, and usage of the drug among U.S. neurologists and geriatricians who manage patients with early AD as well as unspecified dementia or unspecified mild cognitive impairment. With additional DMTs poised to reach the market in 2024, the data will provide insight into drivers and constraints on the use of Leqembi and similar agents and will highlight opportunities to support current and future prescribers to drive uptake.

Questions answered

  • What are the awareness of, familiarity with, and perceptions of Leqembi among U.S. neurologists and geriatricians in year one of its launch?
  • What is the general perception of Leqembi as a treatment for AD among neurologists and geriatricians, and how has the approval of Leqembi impacted their practices?
  • How do the clinical and nonclinical attributes of Leqembi influence physicians’ willingness to prescribe it?
  • To how many patients have they prescribed the drug? How many patients are inquiring about it?
  • What types of assessments are physicians completing at follow-up appointments?
  • What are the main obstacles holding physicians back from administering Leqembi to more of their AD patients? Why have some physicians not yet used Leqembi for AD, and when do they plan to?
  • What factors contribute to treatment discontinuation?

Product description

Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help gauge competitors in shaping their market strategies, identifying potential areas for differentiation, and physician’s receptivity.

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east